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Angiogenesis is a pivotal process of homeostasis and tissue repair, but it also favours neovascularisation
syndromes and cancer nutrition. The chemical mediation of angiogenesis is complex, involving a balance
between serine proteases and their inhibitors. We addressed the mechanisms of action of a Kunitz serine
protease inhibitor (KPI) on spontaneous angiogenesis, using Amblyomin-X, a KPI designed from the
cDNA library of the Amblyomma cajennense tick. Amblyomin-X treatment (10e1000 ng/10 mL; each 48 h;
3 times) reduced the number of vessels in the subcutaneous dorsal tissue of male Swiss mice, as
measured by intravital microscopy, haematoxylin-eosin staining, and PECAM-1 immunoﬂuorescence
labeling. Incubation of Amblyomin-X with t-End endothelial cells, a murine endothelial microvascular
lineage, did not alter cell proliferation, cell-cycle phases, necrosis and apoptosis, and the production of
nitric oxide and prostaglandin E2. Nevertheless, Amblyomin-X treatment reduced t-End migration and
adhesion to Matrigel®, and inhibited the VEGF-A secretion and VCAM-1 and b3 integrin expressions by
posttranscriptional pathways. Together, data herein outline novel posttranscriptional mechanisms of
KPIs on endothelial cells during angiogenesis and point out the possible application of Amblyomin-X as a
local inhibitor to undesired neovascularisation process.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Angiogenesis is crucial from early embryonic to adult stages and
to some adult physiological conditions, including cycling ovaries,
placentation processes (Albrecht and Pepe, 2010), ventricular-
subventricular zone neurogenesis (Sawada et al., 2014), and to
the recovery of haemostasis during wound repair and tissue allo-
graft transplantation (Wietecha and Dipietro, 2013). Nevertheless,
enhanced angiogenesis is involved in the development of solid
cancer by supplying nutrients for growth and metastasis (Welti
et al., 2013), and in the severe neovascularisation syndromes
associated with vision loss (Waltenberger, 2007; Baxter et al., 2013;
Sawhney et al., 2013; Ergul et al., 2014), Alzheimer disease(Cameron et al., 2012; Huang et al., 2013; Ryu et al., 2013), and
chronic rheumatoid arthritis (Shibuya, 2014; De Falco, 2014).
Therefore, anti-angiogenic drug development relies on a knowl-
edge of the molecular mechanisms controlling angiogenesis, which
is pivotal in driving the advancement of speciﬁc therapeutic ap-
proaches (Goel and Mercurio, 2013; Welti et al., 2013; Kwaan et al.,
2013).
Angiogenesis initiates with altered rheological parameters in
the pre-existent blood vessel, characterised by enhanced vascular
permeability and vasodilation, which favours the detachment of
endothelial cells and their passage through the basement mem-
brane. Subsequently, detached cells migrate and proliferate to form
new outgrowths, which reorganise into a patent three-dimensional
tubular structure of the new vessels (Risau, 1997). Endothelial cells
must promptly answer to a gradient of chemical mediators to
activate angiogenesis functions, and the ﬁne balance of chemical
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will orchestrate the process (Ferrara and Kerbel, 2005;
Karamysheva, 2008; Shibuya, 2014).
A balance between serine proteases and their inhibitors is
essential to haemostasis, including the control of angiogenesis
(Masson, 2006; Rau et al., 2007). Inhibitors of serine proteases in
stimulated angiogenesis, especially in cancer conditions, may cause
anti- or pro-angiogenic effects (Murakami et al., 2010; Nishio et al.,
2008; Fang et al., 2014). The controversial data may be due to the
signiﬁcant amount of overlappingmediators secreted in the tumour
microenvironment, which may affect the serine protease/inhibitor
balance (Kwaan et al., 2013). This is exempliﬁed by the actions of
the tissue factor pathway inhibitor 2 (TFPI- 2), themain KPI secreted
by endothelial cells. TFPI-2 inhibits the proliferation, adhesion and
migration of endothelial cells by impairing plasmin formation, re-
duces extravascular metalloprotease enzymes activities (Ivanciu
et al., 2007), and impairs focal adhesion of endothelial cells to the
extravascular matrix (Provençal et al., 2008). Moreover, TFPI-2 gene
and protein expression is up-regulated by vascular endothelial
growth factor-A (VEGF-A) actions (Xu et al., 2006). The latter effect
has been proposed as a feedback mechanism that controls the pro-
angiogenic actions of the growth factors (Xu et al., 2006).
Kunitz protease inhibitors (KPIs) comprise a class of peptides
present in animals, plants and microorganisms, consisting of
approximately 60 amino acid residues. These amino acids contain
conserved cysteine residues forming three disulﬁde bridges, which
confers the compact and stable nature of the folded polypeptide.
KPIs may contain one or multiple Kunitz domains in a single-chain
that interact with different proteases at their reactive sites
(Ranasinghe and McManus, 2013). These characteristics, associated
with a widespread but not uniform KPI expression in the tissues,
lead to different actions of KPIs depending on the microenviron-
ment of the angiogenesis process (Noel et al., 2004).
Animal venoms are an important source of KPIs, which have
been employed as a scientiﬁc tool and are promising therapeutic
approaches, especially for blood and vascular diseases (Chen et al.,
2013). In this context, Amblyomin-X, a recombinant Kunitz-type
FXa inhibitor (GenBank code AAT68575) identiﬁed in the tran-
scriptome of the salivary glands of the Amblyomma cajennense tick
(Batista et al., 2008, 2010) presents anti-tumour and anti-
metastatic activities in vivo (Chudzinski-Tavassi et al., 2010;
Ventura et al., 2013). Interestingly, our studies have demonstrated
Amblyomin-X toxicity to tumour cells, but not to human ﬁbro-
blasts, reinforcing its tissue-speciﬁc actions (Chudzinski-Tavassi
et al., 2010; Maria et al., 2013). Moreover, we showed that
Amblyomin-X inhibited the VEGF-A-induced angiogenesis in mice,
by impairing the homotypic and heterotypic endothelial cell
adhesion (Drewes et al., 2012).
Although Amblyomin-X has similarity to the endogenous tissue
factor pathway inhibitor (TFPI), structural and molecular modelling
studies showed that the pattern of charged residues in the Kunitz
domain of Amblyomin-X was not similar to that in human TFPI-1
and TFPI-2, suggesting distinct functional features to the toxin
(Pasqualoto et al., 2014). Therefore, to extend the knowledge of
different KPIs on endothelial cell functions, and to further suggest
Amblyomin-X as a promising scientiﬁc tool or even therapeutic
agent, we here designed a set of in vivo and in vitro assays to show
the molecular mechanisms of Amblyomin-X action on endothelial
cell functions during angiogenesis.
2. Material and methods
2.1. Reagents
Monoclonal antibodies, Annexin-V and Matrigel® werepurchased from BD PharMingen Technical (San Diego, CA, USA).
Propidium iodide (PI), lipopolysaccharide E.coli (LPS) and Evans
Blue were obtained from Sigma (St. Louis, Mo, USA). RPMI 1640
medium and fetal bovine serum (FBS) were purchased from
Vitrocell (S~ao Paulo, Brazil). The CellTrace CFSE cell proliferation
kit was purchased from Invitrogen (NY, USA), the VEGF kit was
purchased from Immuno-Biological Laboratories (Japan) and the
PGE2 kit was purchased from Cayman Chemical (Michigan, USA).
Reagents for mRNA extraction and RT-PCR experiments were
purchased from Invitrogen and Applied Biosystems, USA,
respectively. Amblyomin-X was obtained according to Batista
et al. (2010).
2.2. Animals
Male Swiss mice (25e30 g) were fed a standard pellet diet and
water ad libitum, and anaesthetised with a mixture of
ketamine(20 mg/kg, i.p.)and xylazine solution (2 mg/kg, i.p.) before
each experimental procedure. All procedures were performed ac-
cording to protocols approved by the Brazilian Society of Science of
Laboratory Animals (SBCAL) for proper care and use of experi-
mental animals and approved by the local ethical committee.
2.3. Cell culture
Polyoma middle T oncogene-transformed mouse endothelioma
cells derived from the thymus (t-End; Willians et al., 1988) were
cultured in RPMI 1640 supplemented with 10% fetal bovine serum
(FBS) in a 5% CO2, humidiﬁed atmosphere, at 37 C. t-End cells were
used at 3rd passage to in vitro studies.
2.4. Intravital microscopic assay: skinfold dorsal chamber
The skinfold dorsal chamber was implanted in male Swiss mice
under anaesthesia as previously described by Harder et al. (2004).
Amblyomin-X (10e1000 ng/10 ml) or saline (control) was topically
applied. The treatment schedule was carried out on the 3rd, 5th
and 7th days after chamber implantation. Animals were immo-
bilised in a polycarbonate tube and the microcirculatory network
visualised in the windows was photographed using a digital
camera (SonyeCyber-Shot e 7.2 Mega Pixels/Optical 3X, Japan)
coupled to intravital microscopy equipment (Carl Zeiss, Germany).
The images obtained before (day 3) and after the treatments (day
9) were quantiﬁed according to Dellian et al. (1996). Results are
expressed as a percentage of the difference of the number of
vessels before and after treatments in each group (n ¼ 5e7 per
group).
To conﬁrm the presence of vessels in a vascular mesh, the skin
was cut in sections (2e3 mm thick, paraffin embedded) and dyed
with Haematoxylin and Eosin (H&E) solution or labelled with
phycoeritrin monoclonal antibody anti-platelet-endothelial cell
adhesion molecule-1 (PECAM-1-PE; CD 31, 1:100).
2.5. Vessel permeability assay
The effect of Amblyomin-X on vessel permeability was investi-
gated according to Senger et al. (1990). Brieﬂy, the animals were
anaesthetised and Evans Blue dye (0.2 mL of 20 mg/kg) was
injected intravenously via the tail vein. Five minutes later, the
dorsal skin was shaved prior to the intradermal (i.d.) injection
(maximum of six sites/mouse) of the saline or Amblyomin-X (10,
100 or 1000 ng/site). Thirty minutes after the i.d. injection of
treatments, animals were sacriﬁced. Their dorsal skinwas removed,
and the injected sites were punched out and weighed. The vessel
permeability was quantiﬁed by spectrophotometric measurement
Fig. 1. Amblyomin-X reduces angiogenesis without any biological or chemical stimulation in dorsal chamber model. The mice were topically treated with Amblyomin-X (10, 100 or
1000 ng/10 mL) in the dorsal skin. The treatments were administrated once a day, at each 2 days, summarizing three applications (A). Representative images of dorsal skin were
obtained before (day 3) and after (day 9) the treatments (B). Representative images of the dorsal skin stained with H&E (C; arrows indicate vessels) and vessels marked with anti-
PECAM-1 (D; arrows indicate PECAM-1 staining) on vascular mesh in the end of treatments. Black bar ¼ 100 mm. The results are expressed as the mean ± s.e.m. from three in-
dependent experiments. **p < 0.01 and ***p < 0.001 compared with Saline group (ANOVA).
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expressed as the Optical Density (OD) ¼ Absorbance 620nm -
Absorbance 690nm x 100. The results are expressed as the OD per-
centage relative to the control group (n ¼ 4e5 per group).2.6. Flow cytometry: cell viability, cell proliferation and adhesion
molecule expression
All experiments were conducted on a FACS Canto Flow Cytom-
eter (Becton Dickinson, Mountain View, CA, USA) and analysed
using the Flow Jo (version 9.1) software. Data from 10,000 events
were obtained and only the morphologically viable endothelial
cells were considered in the analysis.
To investigate the effect of Amblyomin-X on apoptosis and ne-
crosis, Annexin-V-FITC and propidium iodide (PI) double staining
was carried out. Cells were incubated with phosphate-saline buffer
solution (PBS; control) or Amblyomin-X (100 or 1000 ng/mL) with
culture medium supplemented with 10% of fetal bovine serum
(FBS) for 72 h. At the end of the treatments, cells were incubated
with Annexin-V-FITC (1:100) for 20 min at room temperature, PI
(0.5 mg/tube) was added and ﬂow cytometry analysis was imme-
diately carried out. The results are expressed as the percentage of
marked cells.
To investigate the effect of Amblyomin-X on cell proliferation,
adherent cells were labelled with carboxyﬂuorescein diacetate
succinimidyl ester (CFSE) according to the manufacturer's in-
structions. Brieﬂy, the cells were washed with PBS and incubated
with CFSE at a ﬁnal concentration of 5 mM (37 C for 15 min).
Culture medium supplemented with 10% of FBS (1 mL) was addedand the cells were incubated for 30 min. After the incubation, the
cells were washed three times with PBS and incubated with PBS
(control) or Amblyomin-X (10,100 or 1000 ng/ml) for 24, 48 or 72 h.
After the treatment period, cells were ﬁxed and their ﬂuorescence
was analysed by ﬂow cytometry. The results are expressed as
ﬂuorescence intensity and reductions in this parameter indicate an
increment of cell proliferation.
The cell-cycle was evaluated in t-End cells incubated with PBS
(control) or Amblyomin-X (100 ng/ml) for 24, 48 or 72 h. After-
wards, cells were washed with PBS, trypsinised and ﬁxed by adding
cold methanol (75%) for 1 h. DNA was stained with 200 ml of PI
(10 mg/ml) and 20 ml of RNAse (15 mg/ml), and the percentage of
cells in each phase of the cell cycle was determined.
The effect of Amblyomin-X on adhesion molecule expression of
PECAM-1, VCAM-1, b1 and b3 integrin were evaluated on adhered
cells into culture plate incubated with PBS (control) or Amblyomin-
X (100 ng/ml) for 2 h. After this period, cells were removed and
incubated with monoclonal antibody anti-PECAM-1 or anti-
vascular cell adhesion molecule (VCAM-1) conjugated with PE or
anti-b1 integrin or anti-b3 integrin conjugated with FITC, for 20min
at 4 C in the dark. The results are expressed as the median of
ﬂuorescence intensity.2.7. Cell adhesion assay
Adhered cells into culture plate (RPMI, FBS free) were incu-
bated with PBS (control) or Amblyomin-X (10, 100 or 1000 ng/mL)
for 2 h. Afterward, cells were removed using a cell scraper, and
5  104 cells were incubated on previously polymerised Matrigel®
Fig. 2. Amblyomin-X does not alter vascular permeability in vivo. To evaluate the
vascular permeability mice were subjected to intravenous injection of Evans blue dye,
then the dorsal region, were performed intradermal injections of Saline, VEGF (100 ng/
site, positive control) or Amblyomin-X (10, 100 or 1000 ng/site) (A) or co-treatment of
Amblyomin-X plus VEGF (B). Treatment effects were assessed by quantifying the
extravasated dye by spectrophotometry (620 nm). The results are expressed as the
mean ± s.e.m. from four independent experiments. *p < 0.05 and ***p < 0.01 compared
with Saline group (ANOVA).
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non adherent cells and incubated with 0.1% crystal violet dye
(100 mL) for 10 min at room temperature. The cells were washed
(PBS; 4  ) and ﬁxed with acetic acid (50%; 100 mL) and the ab-
sorbencies were obtained at 580 and 690 nm. The values are
expressed as the Optical Density (OD) ¼ Absorbance 580 nm e
Absorbance 690 nm  100. The results are expressed as the OD
percentage relative to the control group.
2.8. Cell migration assay
Conﬂuent t-End cells (1  106) were cultured in a 12-well plate,
and a ‘‘groove’’ in the centre of the well was wounded with a cell
scraper (Burk, 1973). Afterwards, cells were gently washed once
with PBS and incubated with PBS (control) or Amblyomin-X (10,
100 or 100 ng/mL) for 12 h. Cell migration was monitored with
images obtained before and after the treatments using a digital
camera coupled to a microscope (Nikon, magniﬁcation 1). The
number of cell nuclei that crossed the demarcated linewas counted
in three different microscopic ﬁelds.
2.9. Tube formation
The tube formation assay was performed on a Matrigel® layer.
Brieﬂy, Matrigel® was diluted in serum-free medium at a ﬁnal
concentration of 3 mg/ml, and 200 ml was added to each well andincubated at 37 C for 1 h to form a gel layer. Subsequently, t-End
cells (2  104/well) were incubated in 10% FBS-containing medium,
in the presence or absence of Amblyomin-X (100 ng/mL) at 37 C, in
a humid atmosphere with 5% CO2 for 8 h. Afterwards, cells were
incubated in staining solution for 30min at 37 C, and the capillary-
like structures formed in the gel were photographed (Axioskop II,
Carl Zeiss, Germany) and the number of branches was quantiﬁed
using Image J software.
2.10. Griess reaction
Endothelial cells (1  106) were incubated with Amblyomin-X
(10, 100 or 1000 ng/mL) or PBS for 24 h. The amount of the stable
metabolite NO2- in the culture supernatants was measured by a
Griess reaction. Brieﬂy, 100 ml of supernatant was incubated with
100 ml of Griess reagent (1% sulphanilamide solution and 0.1% a-
naphthyl ethyl diamine solution) for 10 min. The absorbance was
monitored at 550 nm using a multiwall plate reader (Power-
WaveX340; Biotek Instruments, Inc.). The results are reported as
mM of NO2.
2.11. Immune assays
Endothelial cells (1  106) were incubated with PBS or
Amblyomin-X (10, 100 or 1000 ng/mL) for 24 h to analyse the
levels of VEGF and PGE2. Concentrations of inﬂammatory media-
tors and growth factors were quantiﬁed in the supernatants using
enzyme-linked immunosorbent assay (EIA) Kits according to the
manufacturer's speciﬁcations and the results are expressed as pg/
ml.
2.12. VCAM-1, b3 integrin and VEGF mRNA expression
The t-End cells were incubated with PBS or Amblyomin-X
(100 ng/mL) for 1 h and total RNA was isolated with TRIzol, and
2 mg of RNA was reverse-transcribed into cDNA using the Super-
Script® VILO™Master Mix (Invitrogen). Quantitative real-time PCR
was performed in a 7500 Fast Real Time PCR System (Applied
Biosystems) using Fast SYBR® Green PCR Master Mix and speciﬁc
primer pairs for: VCAM-1 (sense: ACAGACAGTCCCCTCAATGG; anti-
sense: ACCTCCACCTGGGTTCTCTT), b3 integrin (sense: TGA-
CATCGAGCAGGTGAAAG; anti-sense: GAGTAGCAAGGCCAATGAGC),
VEGF-A (sense: TCACCAAAGCCAGCACATAG; anti-sense:
TTTGACCCTTTCCCTTTCCT) and housekeeping gene RPL13a (ribo-
somal protein L13a) (sense: TCCTCAAGACCAACGGACTCCT; anti-
sense: AACCTTTGGTCCCCACTTCCCT). The cycling program was
95 C for 15min, followed by 40 cycles of 95 C for 15 s and 60 C for
60 s. Each sample was run in duplicate. The expression of each
target gene was normalised to RPL13a relative expression as an
internal efﬁciency control. Values are reported as fold increase
relative to the untreated control.
2.13. Statistical analyses
Means and standard error mean (s.e.m.) of all data are pre-
sented, which were compared by the Student's t-test or ANOVA,
followed by Tukey's Multiple Comparisons. GraphPad Prism 5.0
software (San Diego, CA, USA) was employed. The differences were
considered signiﬁcant when p was less than 0.05.
3. Results
3.1. Effects of Amblyomin-X on in vivo angiogenesis in mice
The local in vivo angiogenic effects of Amblyomin-X on the
Fig. 3. Amblyomin-X does not alter levels chemical mediators and reduce levels of VEGF, without affect gene expression, by t-End cells. To evaluate the levels of NO (A), PGE2 (B) or
VEGF (C) endothelial cells were cultured in the presence or absence of Amblyomin-X (10, 100 or 1000 ng/ml) during 24 h and supernatant was used to evaluate the levels of
mediators by Griess reaction and enzyme-immunoassay, respectively. The VEGF mRNA produced by endothelial cells was evaluated by real time RT-PCR 1 h after treatments (D). The
results are expressed as the mean ± s.e.m. from three independent experiments. ***p < 0.001 compared with PBS group (ANOVA or Student's t-test).
Fig. 4. Amblyomin-X does not alter endothelial cell viability, cell proliferation or cell cycle. Cells t-End was treated with PBS (control) or Amblyomin-X (10, 100 or 1000 ng/mL) and
evaluated by ﬂow cytometer. To evaluate the cell viability (A), apoptosis (B) and late apoptosis (C) the cells were treated (72 h) and incubated Anexin-V-FITC and PI (50 mg/ml, 10 ml/
tube). To evaluate the cell proliferation, the cells were incubated with CFSE for 45 min and subsequently incubated with different treatments. The intensity of ﬂuorescence was
evaluated at 24 h (D), 48 h (E) or 72 h (F) after the treatments. To evaluate the cell cycle the t-End cells were incubated with different treatments for 24 h (G), 48 h (H) or 72 h (I) and
labeled with PI (50 mg/mL). The results are expressed as the mean ± s.e.m. from three independent experiments (ANOVA).
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Fig. 5. Amblyomin-X inhibits endothelial cell adhesion, migration and tube formation. After t-End cells reached conﬂuence it was wounded with a pipette tip, creating a ‘‘groove’’ in
the center of well. Afterward, cells were incubated with PBS (control) or Amblyomin-X (10, 100 or 1000 ng/mL) during 12 h. The migration of the cells was monitored with images
obtained before and after treatments (A, B). After t-End cells incubated with PBS (control) or Amblyomin-X (10, 100 or 1000 ng/mL) during 2 h, remained adhering for 30 min and
were stained with crystal violet dye for 10 min. The adhesion cell on Matrigel® was monitored with absorbance (C). t-End cells were incubated with PBS or Amblyomin-X (100 ng/
mL) on Matrigel® for 8 h and quantiﬁcation of capillary-like structures was made using an optical microscope (D, E). Black bar ¼ 100 mm. The results are expressed as the
mean ± s.e.m. from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 compared with PBS group (ANOVA or Student's t-test).
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H&E staining, and PECAM-1 labelling. Data obtained showed that
topical application of Amblyomin-X (10,100 or 1000 ng/10 mL), each
48 h, signiﬁcantly reduced the number of vessels in the subcu-
taneous tissue of mice compared to PBS treatment (Fig. 1A). The
effect was not dose-dependent and the maximal inhibition on
vessel formation was 35%. The representative images of in vivo
angiogenesis obtained in intravital microscopy experiments, H&E
staining of the vascular network and PECAM-1-labelled cells are
shown in Fig. 1B, C and D, respectively.3.2. Effects of Amblyomin-X on vascular permeability and secretion
of chemical mediators
The intradermal (i.d.) injection of Amblyomin-X (10, 100 or
1000 ng/site) did not affect the microvascular permeability, as
Evans blue extravasation into tissue was equivalent to that evoked
by vehicle (PBS) injection (Fig. 2A). It is important to emphasise that
intradermic injection of VEGF-A (100 ng/site), a known inducer of
microvascular permeability and employed as positive controls for
the experiment, signiﬁcantly increased the microvascular perme-
ability. Additionally, Amblyomin-X did not inactive VEGF-A,
because the in vivo co-administration of VEGF-A and Amblyomin-
X did not abolish the increased vascular permeability evoked by
the growth factor (Fig. 2B).
Treatment of t-End endothelial cells with Amblyomin-X (10, 100
or 1000 ng/mL) did not alter the levels of NO and PGE2 (Fig. 3A and
B), which are involved in the in vivo enhanced vascular perme-
ability during angiogenesis. The treatment of t-End cells with LPS
(5 mg/mL) enhanced NO and PGE2 levels in the supernatant,showing the efﬁcacy of the experiment (NO:
cells þ PBS ¼ 24 ± 0.4 mM/mL, cells þ LPS: 166 ± 0.2 mM/mL; PGE2:
cells þ PBS ¼ 76.5 ± 2 pg/mL, cells þ LPS: 455 ± 2.5 pg/mL).
In contrast, Amblyomin-X treatment reduced VEGF-A concen-
trations in the supernatant of endothelial cells (Fig. 3C), indepen-
dently of gene expression, because VEGF-A mRNA levels were not
reduced in Amblyomin-X-treated cells (Fig. 3D).3.3. Effects of Amblyomin-X on endothelial cell viability,
proliferation and cell cycle
The actions of Amblyomin-X on endothelial cell viability, pro-
liferation and cycle were investigated using ﬂow cytometry. Data
presented in Fig. 4 shows that Amblyomin-X (100 or 1000 ng/mL)
treatment did not cause apoptosis and late apoptosis (Fig. 4AeC). As
positive control, cells were incubated with RPMI depleted serum
(1%), which reduced about 40% of viable cells (2% apoptosis; 8% late
apoptosis and 30% necrosis, data not shown).
Similarly, treatment with Amblyomin-X did not alter cellular
proliferation measured after 24, 48 or 72 h (Fig. 4DeF) either
induced cycle arresting measured until 72 h of incubation
(Fig. 4GeI). Positive control was performed by incubating t-End
with VEGF-A (50 ng/ml), which arrested the percentage of cells in
phase S 48 h after incubation.3.4. Effects of Amblyomin-X on endothelial cell adhesion, migration
and tube formation
The role of Amblyomin-X during endothelial cell adhesion,
migration and tube formation was assessed by spectroscopy and
Fig. 6. Amblyomin-X inhibits expression of adhesion molecule VCAM-1 and b3 integrin on endothelial cell but not inhibit mRNA expression. Endothelial cells were incubated with
culture medium added of PBS (control) or Amblyomin-X (100 ng/mL) during 2 h to evaluate the expression of VCAM-1 (A), b3 integrin (C), PECAM-1 (E) and b1 integrin (F) by ﬂow
cytometry. The cells were incubated with treatments for 1 h to evaluate the levels of mRNA of VCAM-1 (B) and b3 integrin (D) by real time RT-PCR. The results are expressed as the
mean ± s.e.m. from three independent experiments. *p < 0.05, ***p < 0.001 compared with PBS group (t-Test).
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ments reduced cell migration (Fig. 5A and B) and adhesion in the
Matrigel® matrix (10e1000 ng/mL; Fig. 5C). Nevertheless, it was
not concentration related effect, as the reduction caused by 100 ng/
mL was similar to that caused by 1000 ng/mL. In addition, analysis
of tube formation showed that Amblyomin-X treatment (100 ng/
mL) reduced the organisation of new vessels in the Matrigel® in t-
End cells (Fig. 5D and E).3.5. Effects of Amblyomin-X on the expression of adhesion
molecules in endothelial cells is independent of mRNA expression
Based on the reduced adhesion and migration of endothelial
cells after Amblyomin-X treatment, the effects of Amblyomin-X on
the basal expression of adhesion molecules PECAM-1, VCAM-1, b3
and b1 integrins in endothelial cells were investigated using ﬂow
cytometry. The treatment with Amblyomin-X (100 ng/mL) reduced
the expression of VCAM-1 (48 ± 13%) and b3 integrin (83 ± 0.8%)
(Fig. 6A and C). Amblyomin-X treatment did not alter PECAM-1 or
b1 integrin expression levels (Fig. 6E and F).Real-time RT-PCR analysis showed that Amblyomin-X treatment
increased the mRNA expression of VCAM-1 but not that of b3
integrin (Fig. 6B and D, respectively).4. Discussion
Therapeutic approaches for targeting complex processes such as
angiogenesis require a fundamental understanding of the molec-
ular control of cellular mechanisms. In this context, venom toxins
have been employed as scientiﬁc tools to elucidate the molecular
mechanisms regulating physiological and pathological conditions.
Indeed, data here presented clearly show that the recombinant KPI
protein Amblyomin-X alters post-transcriptional mechanisms in
endothelial cells, which may be relevant for the impaired in vitro
and in vivo angiogenesis caused by its local application.
Intravital microscopy has been highly utilised to evaluate
tumour angiogenesis or that induced by exogenous chemical
substances, as well as to evaluate the actions of anti-angiogenic
agents (Drewes et al., 2012; Gellrich et al., 2014). Here, we eval-
uated the anti-angiogenic actions of Amblyomin-X in the absence
Fig. 7. Proposal pathway of Amblyomin-X actions on angiogenesis. Arrows indicate actions of Amblyomin-X on steps of angiogenesis process.
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gical procedure to skinfold dorsal chamber implants. The inhibi-
tory action of Amblyomin-X on vessel formationwas conﬁrmed by
histological and immunoﬂuorescence analyses. It is noteworthy to
mention that PECAM-1 ﬂuorescence labelling was crucial to
indicate that the reduced number of vessels did not reﬂect an
alteration of vessel rheology, as blood ﬂow and vessel diameter,
because PECAM-1 is constitutively expressed by endothelial cells
and is used as a marker of vessel walls (Takase et al., 2013; Eman
et al., 2014). In addition, Amblyomin-X treatment did not alter
PECAM-1 expression by t-End cells, corroborating that PECAM-1
labelling is reliable for the analysis of vessel formation in the
present study.
The observation that Amblyomin-X did not cause in vivo local
alterations in vascular permeability reinforces that the protein does
not present a direct action on endothelial contractile mechanisms.
In addition, Amblyomin-X treatment did not affect the production
of important inducers of vascular permeability, NO and PGE2 by
endothelial cells. Nevertheless, Amblyomin-X reduced VEGF-A
secretion by a post-transcriptional mechanism. As VEGF-A is also
a potent enhancer of vascular permeability (Shibuya, 2014), it may
be suggested that the combination of endogenous vascular factors,
such as histamine, serotonin, PGE2 and NO, on angiogenesis may be
responsible for the in vivo normal vascular permeability after
Amblyomin-X injection. Additionally, co-administration of
Amblyomin-X did not alter the enhanced vascular permeability
evoked by exogenous administration of VEGF-A, indicating that
Amblyomin-X does not modify the VEGF-A pathways responsible
for endothelial cell contraction during the enhanced vascular
permeability.
To our knowledge this is the ﬁrst evidence for the post-
transcriptional control of a KPI on VEGF-A secretion by endothe-
lial cells. VEGF-A interacts with vascular endothelial growth factor
receptors (VEGFRs 1 and 2) on cell membranes and triggers
downstream intracellular mechanisms to physiological and path-
ological angiogenesis. VEGF-A induces endothelial permeability,
proliferation, migration and adhesion during the process (Shibuya,
2014). Indeed, Amblyomin-X treatment reduced the adhesion and
migration of endothelial cells; nevertheless, the direct actions of
Amblyomin-X on endothelial cell adhesion and locomotion prop-
erties, or the dependence of reduced levels of VEGF-A caused by
Amblyomin-X treatment remain to be clariﬁed.
In vitro angiogenesis in a matrix mimetic system depends onhomotypic and heterotypic endothelial cell adhesion. It is note-
worthy to mention that the matrix system employed presents li-
gands to endothelial surface ligands, such as collagen, laminin and
entactin. As different integrins subtypes bind into these ligands
(Stupack and Cheresh, 2002, Weis and Cheresh, 2011; Plow et al.,
2014), it may be supposed that Amblyomin-X may modulate the
activities of these proteins or the expression of adhesion molecules
in endothelial cells, reducing cell adhesion and tube formation
process. Therefore, the role of Amblyomin-X on adhesion molecule
expression in endothelial cells was further investigated. Indeed,
Amblyomin-X treatment reduced the expression of VCAM-1 and b3
integrin by t-End cells. VCAM-1 is linked to the endothe-
lialeextravascular matrix and endothelialeleukocyte interactions
(Schlesinger and Bendas, 2015; Kang et al., 2014), and b3 integrin is
a subfamily of heterodimers (of which avb3 integrin is the most
important representative in the angiogenesis process) (Francavilla
et al., 2009). The role of both VCAM-1 and avb3 integrin on angio-
genesis has been fully shown by in vitro and in vivo molecular and
pharmacological approaches (Schlesinger and Bendas, 2015; Kang
et al., 2014). Recent data corroborate that KPI controls sponta-
neous angiogenesis, which may involve inhibitions of the expres-
sion and function of adhesion molecules. A KPI isolated from
Macrovipera lebetina snake venom inhibited spontaneous human
vascular endothelial cell adhesion, migration onto ﬁbrinogen and
ﬁbronectin, and tube formation (Morjen et al., 2014). These effects
depended on the instability of microtubule assembly, which may
involve the interference with a5b1 and avb3 integrin functions
(Morjen et al., 2014).
The direct actions of KPIs on adhesion molecule expression is
not fully understood, and our data highlight the post-
transcriptional actions of Amblyomin-X on expression of VCAM-1
or b3 integrin. This conclusion is reinforced by normal and
elevated mRNA levels of VCAM-1 and b3 integrin, respectively, and
reduced protein expression of both adhesion molecules on cell
membranes. The role of reduced secretion of VEGF-A after
Amblyomin-X treatment on impaired adhesion molecule expres-
sion may not be ruled out, as both pre- and post-transcriptional
pathways may be involved in VEGF-A-induced adhesion molecule
expressions (Kim et al., 2003; Fearnley et al., 2014). Although the
majority of data indicate the transcriptional control of VEGF-A on
adhesion molecules, it has recently been shown that VEGF-A in-
duces a direct interaction between the urokinase plasminogen
activator receptor (uPAR) and integrins, leading to integrin
C.C. Drewes et al. / Toxicon 101 (2015) 1e10 9membrane redistribution and focal adhesion during angiogenesis.
Reduced VEGF-A levels could impair uPAR-integrin interactions,
reducing in vitro endothelial cell migration and in vivo angiogenesis
(Alexander et al., 2012; Uhrin and Breuss, 2013; Montuori and
Ragno, 2014). However, further studies are required to conﬁrm
the role of Amblyomin-X/VEGF-A/adhesion molecule expression in
impaired angiogenesis.
In conclusion, data here highlight novel mechanisms of KPIs
during the angiogenesis process, and implicate Amblyomin-X as a
scientiﬁc tool for understanding the physiological and pathological
pathways of vascular diseases (Fig. 7). Furthermore, our data
emphasise that further studies must be carried out to validate the
use of Amblyomin-X as a local therapeutic agent in aberrant neo-
vascularisation syndromes.
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